文献速递腹部MR

钆塞酸增强与扩散加权MR成像识别细胞角蛋白19阳性肝细胞癌的影像特征:一项回顾性观察研究

Imaging Features of Gadoxetic Acid-enhanced and Diffusion-weighted MR Imaging for Identifying Cytokeratin 19-positive Hepatocellular Carcinoma: A Retrospective Observational Study.
PubMed 文献 · Radiology · 2017-11-21

本回顾性观察研究在单中心纳入204例CK19阴性及38例CK19阳性肝细胞癌患者,评估钆塞酸增强与扩散加权MR术前表现。多因素分析显示不规则肿瘤边缘、动脉期环形强化、肝胆期肿瘤/肝信号强度比≤0.522及ADC比值≤0.820为独立预测因素;满足四项标准时特异度达99.5%。CK19阳性组根治性切除后无复发生存率显著低于阴性组。

要点

  • 不规则肿瘤边缘、动脉期环形强化、肝胆期肿瘤/肝信号强度比≤0.522及ADC比值≤0.820为CK19阳性HCC独立预测因素。
  • 四项标准全部满足时特异度99.5%(203/204),满足三项时识别63.2%(24/38)的CK19阳性HCC,特异度90.7%(185/204)。
  • CK19阳性HCC根治性切除后无复发生存率显著低于CK19阴性HCC(1年63.9% vs 90.0%,P=.001)。

核心结论

  • 在钆塞酸增强与扩散加权MR成像上,不规则边缘、动脉期环形强化、较低的肿瘤/肝ADC比值及较低的肝胆期肿瘤/肝信号强度比可能有助于预测CK19阳性HCC及其根治性切除后早期(<2年)复发。

关键影像表现/征象

  • 不规则肿瘤边缘在多因素分析中为CK19阳性HCC的独立预测因素(P=.024)。
  • 动脉期环形强化在多因素分析中为CK19阳性HCC的独立预测因素(P<.001)。
  • 肝胆期肿瘤/肝信号强度比≤0.522为CK19阳性HCC的独立预测因素(P=.01)。
  • 肿瘤/肝ADC比值≤0.820为CK19阳性HCC的独立预测因素(P<.001)。

诊断标准与关键数值

  • 满足四项标准中三项时,识别63.2%(24/38;95%CI:46.0%,78.2%)的CK19阳性HCC,特异度90.7%(185/204;95%CI:46.0%,78.2%)。
  • 四项标准全部满足时,特异度99.5%(203/204;95%CI:97.3%,100%)。
  • 定量变量最佳截断值:肝胆期肿瘤/肝信号强度比≤0.522,肿瘤/肝ADC比值≤0.820。

临床应用与阅片要点

  • 阅片时可关注肿瘤边缘是否规则、动脉期有无环形强化,并测量肝胆期肿瘤/肝信号强度比及肿瘤/肝ADC比值。
  • 四项标准全部满足时特异度达99.5%,满足三项时识别63.2%的CK19阳性HCC,特异度90.7%。
  • CK19阳性HCC根治性切除后无复发生存率显著低于CK19阴性HCC(1年63.9% vs 90.0%,2年63.9% vs 79.9%,3年54.8% vs 70.2%,P=.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To determine the preoperative magnetic resonance (MR) imaging findings potentially most useful for predicting cytokeratin 19 (CK19)-positive hepatocellular carcinoma (HCC) and to evaluate the prognosis after curative resection in patients with a single HCC lesion positive for CK19 compared with patients with HCC who are negative for CK19. Materials and Methods The institutional review board approved this study and waived the requirement for informed consent. Two hundred four patients with CK19-negative HCC and 38 with CK19-positive HCC who underwent curative resection after gadoxetic acid-enhanced and diffusion-weighted MR imaging were retrospectively evaluated in a single institution. Two radiologists evaluated preoperative findings at MR imaging. Significant findings for differentiating the two groups were identified at univariate and multivariate analyses. By using receiver operating characteristic analysis, the optimal cut-off values for quantitative variables were determined. Recurrence-free survival rates after surgery were also compared between groups. Results At multivariate analysis, irregular tumor margin (P = .024), arterial rim enhancement (P < .001), lower tumor-to-liver signal intensity (SI) ratio on hepatobiliary phase (HBP) images (≤0.522; P = .01), and lower tumor-to-liver apparent diffusion coefficient (ADC) ratio (≤0.820; P < .001) were independent significant factors to predict CK19-positive HCC. When three of these four criteria were combined, 63.2% (24 of 38; 95% confidence interval: 46.0%, 78.2%) of CK19-positive HCCs were identified with a specificity of 90.7% (185 of 204; 95% confidence interval: 46.0%, 78.2%). When all four criteria were satisfied, specificity was 99.5% (203 of 204; 95% confidence interval: 97.3%, 100%). Recurrence-free survival rates were significantly lower in patients with CK19-positive HCCs compared with those with CK19-negative HCCs after curative resection (63.9% vs 90.0% at 1 year, 63.9% vs 79.9% at 2 years, and 54.8% vs 70.2% at 3 years, P = .001 by log-rank test). Conclusion At gadoxetic acid-enhanced and diffusion-weighted MR imaging, irregular margin, arterial phase rim enhancement, lower tumor-to-liver ADC ratio, and lower tumor-to-liver SI ratio at HBP imaging may be helpful to predict CK19-positive HCC with early recurrence (<2 years) after curative resection. © RSNA, 2017 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Choi SY, Kim SH, Park CK, et al. Imaging Features of Gadoxetic Acid-enhanced and Diffusion-weighted MR Imaging for Identifying Cytokeratin 19-positive Hepatocellular Carcinoma: A Retrospective Observational Study. Radiology. 2017. PMID: 29166246. doi:10.1148/radiol.2017162846

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。